Capital One Financial upgraded shares of Kodiak Sciences (NASDAQ:KOD – Free Report) from an equal weight rating to an overweight rating in a report published on Friday, Marketbeat Ratings reports. They currently have $12.00 price target on the stock, up from their previous price target of $7.00.
KOD has been the subject of several other research reports. JPMorgan Chase & Co. downgraded shares of Kodiak Sciences from a neutral rating to an underweight rating in a research report on Monday, July 24th. UBS Group downgraded shares of Kodiak Sciences from a buy rating to a neutral rating and cut their price objective for the stock from $15.00 to $4.00 in a research report on Thursday, July 27th. Jefferies Financial Group downgraded shares of Kodiak Sciences from a buy rating to a hold rating in a research report on Monday, July 24th. Finally, Chardan Capital downgraded shares of Kodiak Sciences from a buy rating to a neutral rating in a research report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of Hold and a consensus price target of $8.67.
Kodiak Sciences Stock Down 2.4 %
Institutional Trading of Kodiak Sciences
A number of hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC boosted its holdings in Kodiak Sciences by 253.6% in the third quarter. Acadian Asset Management LLC now owns 1,636,621 shares of the company’s stock worth $2,945,000 after purchasing an additional 1,173,832 shares during the period. Silverarc Capital Management LLC acquired a new position in Kodiak Sciences in the third quarter worth $2,006,000. Newtyn Management LLC boosted its holdings in Kodiak Sciences by 62.5% in the third quarter. Newtyn Management LLC now owns 1,608,694 shares of the company’s stock worth $2,896,000 after purchasing an additional 618,991 shares during the period. BlackRock Inc. boosted its holdings in Kodiak Sciences by 20.5% in the first quarter. BlackRock Inc. now owns 3,435,960 shares of the company’s stock worth $26,526,000 after purchasing an additional 584,762 shares during the period. Finally, Bruce & Co. Inc. acquired a new position in Kodiak Sciences in the first quarter worth $2,933,000. Hedge funds and other institutional investors own 80.99% of the company’s stock.
Kodiak Sciences Company Profile
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
- Five stocks we like better than Kodiak Sciences
- Stock Sentiment Analysis: How it Works
- The most upgraded stocks in November have two things in common
- How to Invest in Hotel Stocks
- Monday.com rocked earnings like it’s the weekend
- What is the Nikkei 225 index?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.